4,4′-Bis(2-Bromoacetyl)biphenyl CAS 4072-67-7 Daclatasvir Dihydrochloride Intermediate Purity>98.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. ndiyo inotungamira kugadzira 4,4'-Bis(2-Bromoacetyl) biphenyl (CAS: 4072-67-7) ine mhando yepamusoro.Ruifu Chemical inogona kupa kutumirwa kwepasirese, mutengo wemakwikwi, sevhisi yakanakisa, idiki uye yakawanda huwandu huripo.Tenga 4,4'-Bis(2-Bromoacetyl)biphenyl,Please contact: alvin@ruifuchem.com
| Chemical Name | 4,4'-Bis(2-Bromoacetyl)biphenyl |
| Mashoko anoreva zvakafanana | 4,4'-Bis(Bromoacetyl)biphenyl;1,1'-[1,1'-Biphenyl]-4,4'-diylbis[2-Bromoethan-1-one];Daclatasvir Kusachena 7 |
| Stock Status | MuStock, Commercial Production |
| Nhamba yeCAS | 4072-67-7 |
| Molecular Formula | C16H12Br2O2 |
| Molecular Weight | 396.07 g/mol |
| Melting Point | 226.0~227.0℃ |
| Density | 1.622±0.06 g/cm3 |
| COA & MSDS | Available |
| Origin | Shanghai, China |
| Category | Pakati peDaclatasvir Dihydrochloride (CAS: 1009119-65-6) |
| Brand | Ruifu Chemical |
| Items | Zvinotsanangurwa | Results |
| Chitarisiko | Solid | Solid |
| Kuchena / Analysis Method | >98.0% (HPLC) | 98.5% |
| Infrared Spectrum | Zvinoenderana NeChimiro | Zvinoenderana |
| 1H NMR Spectrum | Zvinoenderana NeChimiro | Zvinoenderana |
| Mhedziso | Chigadzirwa chakaedzwa uye chinoenderana nezvakapihwa | |
| Application | Pakati peDaclatasvir Dihydrochloride (CAS: 1009119-65-6) | |
Package:Fluorinated Bhodhoro, Aluminium foil bag, 25kg/Cardboard Drum, kana zvinoenderana nezvinodiwa nemutengi.
Storage Condition:Chengetedza mudziyo wakavharwa zvakasimba uye chengeta muimba inotonhorera, yakaoma uye ine mhepo yakanaka kure nezvinhu zvisingaenderani.Dzivirira kubva kuchiedza uye unyoro.
KutumiraKuendesa kupasirese nemhepo, neFedEx / DHL Express.Ipa kutumirwa nekukurumidza uye kwakavimbika.
Kutenga sei?Please contactDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
Makore 15 Oupenyu?Tine makore anopfuura 15 ane ruzivo mukugadzira uye kutumira kunze kwemhando dzakasiyana-siyana dzepamusoro dzemishonga yepakati kana makemikari akanaka.
Main Markets?Tengesa kumusika wepamba, North America, Europe, India, Korea, Japan, Australia, nezvimwe.
Zvakanakira?Hunhu hwepamusoro, mutengo unokwanisika, masevhisi ehunyanzvi uye rutsigiro rwehunyanzvi, kuendesa nekukurumidza.
HunhuSimbiso?Strict quality control system.Midziyo yehunyanzvi yekuongorora inosanganisira NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, nezvimwe.
Samples?Zvigadzirwa zvakawanda zvinopa mahara emahara ekuongorora kwemhando, mutengo wekutumira unofanirwa kubhadharwa nevatengi.
Factory Audit?Factory audit inogamuchirwa.Ndapota itai nguva isati yasvika.
MOQ?Hapana MOQ.Kurongeka kudiki kunogamuchirwa.
Delivery Nguva? Kana mukati me stock, mazuva matatu kutumirwa anovimbiswa.
Transportation?Ne Express (FedEx, DHL), neMhepo, neGungwa.
Zvinyorwa?Mushure mekutengesa sevhisi: COA, MOA, ROS, MSDS, nezvimwe zvinogona kupihwa.
Custom Synthesis?Inogona kupa echinyakare synthesis masevhisi kuti aenderane nezvinodiwa zvako zvekutsvagisa.
Payment Terms?Proforma invoice inozotumirwa kutanga mushure mekusimbisa kurongeka, yakavharirwa ruzivo rwedu rwebhangi.Kubhadhara neT/T (Telex Transfer), PayPal, Western Union, nezvimwe.
4,4'-Bis(2-Bromoacetyl) biphenyl (CAS: 4072-67-7) iri pakati peDaclatasvir Dihydrochloride (CAS: 1009119-65-6).
Daclatasvir Dihydrochloride (Daklinza) inhibitor ye hepatitis C virus (HCV) NS5A inobatsira mukurapa genotype 3 chirwere chisingaperi chehepatitis C.
Musi waChikunguru 24, 2015, iyo FDA yakabvumidza mushonga usingaperi wehepatitis C (Bristol-Myers Squibb) wekushambadzira.
Iyo FDA yekubvumidza maitiro eDaklinza (Bristol-Myers squibb) yakachinja-chinja.Yakamborambwa neFDA, asi pakupedzisira yakabvumidzwa pakati pe2015.Iyo FDA yakabvumidza musanganiswa weDaklinza neSofosbuvir pakurapa hepatitis C gene Type 3 varwere.
Muchokwadi, sekutanga kusati kwabvumidzwa neFDA, Daklinza yakanga yabvumidzwa kushambadzira muJapan, European Union neSouth Korea nedzimwe nyika.Muna 2014, chikamu chehutano cheJapan chakabvumidza kushandiswa kweDaklinza uye Asunaprevir (Sunvepra) pakurapa genotype 1 chirwere.European Union yakabvumirawo kuti Daclatasvir ishandiswe pamwe chete nemimwe mishonga mukurapa HCV genotypes 1, 2, 3 uye 4 muna 2014. Daclatasvir ndiyo yekutanga NS5A complex inhibitor yakagamuchirwa neEuropean Union (EU).Kana yakashandiswa pamwe chete nemamwe madhiragi, ichienzaniswa nekubatanidzwa kwekurapa kwe interferon uye ribavirin iyo inotora mavhiki makumi mana nemasere, ine nguva pfupi yekurapa (masvondo gumi nemaviri kana mavhiki makumi maviri nemana).
Daclathavir monotherapy haikurudzirwe, ikozvino mainstream protocol ndeye musanganiswa kurapa kweDacastavir+ Sofosbuvir, iyo inoratidzirwa nekushanda kwakanaka, yakakwirira SVR, diki mhedzisiro uye kupfupikiswa kwekurapa kutenderera pane dzimwe sarudzo.
